Literature DB >> 17695247

Initiation of primary anti-vaccinia virus immunity in vivo.

Matthew A Fischer1, Christopher C Norbury.   

Abstract

The primary focus of our work is the initiation of an antiviral immune response. While we employ many experimental systems to address this fundamental issue, much of our work revolves around the use of vaccinia virus. Concerns over the negative effects of vaccination have prevented the return of the smallpox immunization program to the general population and underscored the importance of understanding the primary immune response to vaccinia virus. This response is comprised of a complex symphony of immune system components employing a variety of different mechanisms. In this review, we will both highlight the roles of many of these components and touch on the applications of vaccinia virus in the laboratory and the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695247     DOI: 10.1007/bf02685894

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  144 in total

1.  Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.

Authors:  J W Hodge; D W Grosenbach; A N Rad; M Giuliano; H Sabzevari; J Schlom
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

2.  Irreversible association of peptides with class II MHC molecules in living cells.

Authors:  A Lanzavecchia; P A Reid; C Watts
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

3.  Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC.

Authors:  M S Malnati; S Ceman; M Weston; R DeMars; E O Long
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

4.  Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum.

Authors:  R Busch; I Cloutier; R P Sékaly; G J Hämmerling
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

5.  Recognition and destruction of virus-infected cells by human gamma delta CTL.

Authors:  J F Bukowski; C T Morita; M B Brenner
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

6.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection.

Authors:  I A Ramshaw; M E Andrew; S M Phillips; D B Boyle; B E Coupar
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

7.  Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins.

Authors:  K Mossman; C Upton; R M Buller; G McFadden
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

8.  Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication.

Authors:  N Harris; R M Buller; G Karupiah
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  THE FATE OF VACCINIA VIRUS ON CULTIVATION IN VITRO WITH KUPFFER CELLS (RETICULO-ENDOTHELIAL CELLS).

Authors:  J W Beard; P Rous
Journal:  J Exp Med       Date:  1938-05-31       Impact factor: 14.307

10.  The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs.

Authors:  D A Hume; A P Robinson; G G MacPherson; S Gordon
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  2 in total

1.  Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.

Authors:  Zhidong Hu; Jing Wang; Yanmin Wan; Lingyan Zhu; Xiaonan Ren; Sugan Qiu; Yanqin Ren; Songhua Yuan; Xiangqing Ding; Jian Chen; Chenli Qiu; Jun Sun; Xiaoyan Zhang; Jim Xiang; Chao Qiu; Jianqing Xu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

2.  The smallpox vaccine induces an early neutralizing IgM response.

Authors:  Juan E Moyron-Quiroz; Megan M McCausland; Robin Kageyama; Alessandro Sette; Shane Crotty
Journal:  Vaccine       Date:  2009-10-12       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.